Corcept Therapeutics Incorporated Stock Analysis

Corcept Stock Analysis Notes

About 86.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.61. Corcept Therapeutics had not issued any dividends in recent years. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 238 people. For more info on Corcept Therapeutics Incorporated please contact the company at 650 327 3270 or go to https://www.corcept.com.

Corcept Therapeutics Investment Alerts

Corcept Therapeutics Upcoming and Recent Events

Corcept Largest EPS Surprises

View All Earnings Estimates

Corcept Therapeutics Environmental, Social, and Governance (ESG) Scores

Corcept Stock Institutional Investors

Note, although Corcept Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Corcept Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.8 B.

Corcept Profitablity

The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26.

Management Efficiency

Corcept Therapeutics has return on total asset (ROA) of 0.13 % which means that it generated a profit of $0.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2577 %, meaning that it created $0.2577 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.16 in 2025. Return On Capital Employed is likely to gain to 0.20 in 2025. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 750.5 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2025.

Technical Drivers

As of the 20th of January, Corcept Therapeutics shows the Mean Deviation of 2.22, downside deviation of 2.51, and Risk Adjusted Performance of 0.1087. Corcept Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Corcept Therapeutics Price Movement Analysis

Corcept Therapeutics Insider Trading Activities

Corcept Therapeutics Predictive Daily Indicators

Corcept Therapeutics Corporate Filings

Corcept Therapeutics Forecast Models

Corcept Therapeutics' time-series forecasting models are one of many Corcept Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Corcept Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Corcept Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Corcept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Corcept Therapeutics. By using and applying Corcept Stock analysis, traders can create a robust methodology for identifying Corcept entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Corcept analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Corcept analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Corcept Therapeutics Incorporated stock analysis indicators help investors evaluate how Corcept Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Corcept Therapeutics shares will generate the highest return on investment. By understating and applying Corcept Therapeutics stock analysis, traders can identify Corcept Therapeutics position entry and exit signals to maximize returns.

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.